Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

Navan will be the first large company to debut without a fully functioning Securities and Exchange Commission.

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Medline named multi-year preferred supplier deals, international expansion and takeovers as ways it will drive further growth ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

Pollon Life, a Chinese biotech company backed by Jack Ma’s Yunfeng Capital, has confidentially filed for a Hong Kong IPO that could raise about USD 300 million. The firm, maker of China’s first ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...

Currently, the listing process for SGX Mainboard involves reviews by both MAS and SGX RegCo. MAS reviews the issuer’s ...

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...

Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ambitions are getting a big boost from the biotech’s market debut. His ...

The China Securities Regulatory Commission (CSRC) issued new guidelines to reform the offline IPO placement mechanism, giving ...